Randomized phase III oncology trials: a survey and empirical Bayes inference
DOI10.1007/S42519-019-0049-4zbMATH Open1425.62144OpenAlexW2956578196WikidataQ106577221 ScholiaQ106577221MaRDI QIDQ2321782FDOQ2321782
Authors: Changyu Shen, Huiping Xu 
Publication date: 23 August 2019
Published in: Journal of Statistical Theory and Practice (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1007/s42519-019-0049-4
Recommendations
- Bayesian Approaches to Randomized Trials
- The estimated and theoretical assurances and the probabilities of launching a phase III trial
- Is the FDA too conservative or too aggressive?: a Bayesian decision analysis of clinical trial design
- A Bayesian Approach to the Design of Phase II Clinical Trials
- Handbook of statistics in clinical oncology
Applications of statistics to biology and medical sciences; meta analysis (62P10) Sampling theory, sample surveys (62D05)
Cites Work
- Title not available (Why is that?)
- Inference and missing data
- Optimal Rates of Convergence for Deconvolving a Density
- Parametric Empirical Bayes Inference: Theory and Applications
- Bayesian statistics and the efficiency and ethics of clinical trials
- Title not available (Why is that?)
- Empirical Bayes deconvolution estimates
Cited In (5)
- The estimated and theoretical assurances and the probabilities of launching a phase III trial
- A fiducial approach to the nonparametric deconvolution problem: the discrete case
- Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- P-hacking in clinical trials and how incentives shape the distribution of results across phases
Uses Software
This page was built for publication: Randomized phase III oncology trials: a survey and empirical Bayes inference
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2321782)
